Ginkgo Bioworks Holdings, Inc.
DNA
$10.76
-$0.43-3.84%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 49.60M | 48.32M | 43.85M | 89.05M | 56.21M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 49.60M | 48.32M | 43.85M | 89.05M | 56.21M |
| Cost of Revenue | 14.82M | 12.05M | 9.62M | 12.00M | 13.72M |
| Gross Profit | 34.78M | 36.27M | 34.23M | 77.04M | 42.49M |
| SG&A Expenses | 43.28M | 49.04M | 51.99M | 52.29M | 66.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | 4.29M | -- | -- | -- |
| Total Operating Expenses | 111.47M | 136.30M | 137.98M | 141.30M | 214.23M |
| Operating Income | -61.87M | -87.98M | -94.14M | -52.26M | -158.02M |
| Income Before Tax | -60.58M | -90.87M | -107.86M | -56.78M | -216.99M |
| Income Tax Expenses | -283.00K | 88.00K | -325.00K | -375.00K | 190.00K |
| Earnings from Continuing Operations | -60.30M | -90.96M | -107.53M | -56.40M | -217.18M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -60.30M | -90.96M | -107.53M | -56.40M | -217.18M |
| EBIT | -61.87M | -87.98M | -94.14M | -52.26M | -158.02M |
| EBITDA | -46.07M | -72.62M | -78.49M | -35.09M | -140.69M |
| EPS Basic | -1.10 | -1.68 | -2.00 | -1.08 | -4.23 |
| Normalized Basic EPS | -0.65 | -0.94 | -1.00 | -0.48 | -1.77 |
| EPS Diluted | -1.10 | -1.68 | -2.00 | -1.08 | -4.23 |
| Normalized Diluted EPS | -0.65 | -0.94 | -1.00 | -0.48 | -1.77 |
| Average Basic Shares Outstanding | 54.86M | 54.24M | 53.81M | 52.24M | 51.37M |
| Average Diluted Shares Outstanding | 54.86M | 54.24M | 53.81M | 52.25M | 51.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |